Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K current report with the SEC on April 28, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Rocket Pharmaceuticals agreed to sell its Rare Pediatric Disease Priority Review Voucher for $180 million cash.
ROCKET PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Rocket Pharmaceuticals agreed to sell its Rare Pediatric Disease Priority Review Voucher for $180 million cash
- Proceeds monetize the KRESLADI approval-related asset and could strengthen near-term liquidity
- Closing remains subject to customary conditions, including Hart-Scott-Rodino waiting-period expiration or termination
- Transaction terms include customary representations, covenants, and indemnification provisions with limitations
Item 7.01 · Regulation FD Disclosure
- Forward-looking statements concern planned proceeds from PRV monetization and expected cash runway
- PRV proceeds deployment and financial position remain subject to change
- Disclosure provides no new operating or financial metrics; investor focus remains execution and liquidity risk
Item EX-99.1 · Exhibit EX-99.1
- $180 million PRV sale provides non-dilutive capital, avoiding equity dilution for shareholders
- Cash runway extended into Q2 2028, reducing near-term financing risk
- Proceeds support cardiovascular programs in Danon disease, PKP2-ACM, and BAG3-DCM
- PRV monetization follows FDA accelerated approval of KRESLADI, strengthening capital allocation flexibility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ROCKET PHARMACEUTICALS, INC. 8-K filings
Get the next RCKT 8-K as it lands
Follow RCKT for push alerts, or ask the research agent what this filing means.